|
|
| Catalog Number |
D138503 |
| Medical Device Problem Code |
Fluid/Blood Leak (1250)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
11/19/2025
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
It was reported that a patient underwent a cardiac ablation procedure with a vizigo and there was blood leakage from the hemostatic valve.It was reported by the customer that blood leaked from the hemostatic valve of the vizigo sheath.Therefore, the sheath was replaced with another new one.The physician commented that the cause of the blood leakage might have resulted from repeatedly removing and reinserting the optrell while it was inside the vizigo sheath.Additional information received indicating the hemostatic valve was not dislodged inside or outside of the hub and the brim cap/hub did not detach from the sheath.The issue occurred while the device was being used on the patient but no air entered the patient¿s body.The blood loss was a few drops, but the exact amount is unknown.
|
| |
|
Additional Manufacturer Narrative
|
|
On 12-dec-2025 the bwi product analysis lab received the complaint device for evaluation.The product analysis has begun but is not completed at this time.When the investigational analysis has been completed, a supplemental 3500a report will be submitted.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster inc., or its employees that the report constitutes an admission that the product, biosense webster inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's ref.(b)(4).
|
| |
|
Additional Manufacturer Narrative
|
|
It was reported that a patient underwent a cardiac ablation procedure with a vizigo and there was blood leakage from the hemostatic valve.Device evaluation details: the device was returned to johnson & johnson medtech (j&j) for evaluation.A visual inspection evaluation and irrigation test of the returned device were performed following johnson & johnson medtech procedures.Visual analysis of the returned sample revealed that no damage was observed on the vizigo sheath.Microscopic examination of the hemostatic valve surface does not show stress marks on the outer diameter.Then, an irrigation test was performed and no leakage, air, or bubbles were observed.A device history record was performed, and no internal actions related to the reported complaint were identified.The leak issue reported by the customer could not be replicated during the product investigation; other issues or circumstances may have occurred during the usage of the device that compromised its performance.The instructions for use (ifu) contain the following information: before inserting the sheath into the patient, flush the sheath and dilator with heparinized normal saline to remove air bubbles and any potential particulate.After the sheath is in the left atrium of the patient, maintain a constant flow of heparinized normal saline to the sheath to minimize the risk of air emboli.Use best practices for inserting or retracting any device at the hemostatic valve.Monitor any potential air entrapped and completely aspirate any observed air out of the side port.Once the sheath is inserted into the vasculature and the dilator is removed, aspirate until steady blood return is achieved prior to flushing or infusion.All fluid infusion should be through the side port.In order to minimize the risk of air embolism provide a continuous infusion of heparinized saline solution once the sheath is inserted into the patient.Slowly remove or insert the dilator or other devices.As part of the quality process, all devices are manufactured, inspected, and released to approved specifications.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Manufacturer's ref.#: (b)(4).
|
| |
|
Search Alerts/Recalls
|
|
|